Creative Medical Receives U.S. Patent Allowance for Exosome-Based Type 1 Diabetes Immunotherapy
核心洞察
Creative Medical Technology Holdings (搜索) received a USPTO Notice of Allowance for a patent covering exosome-based immunotherapy targeting Type 1 diabetes (搜索).
The allowed patent protects the MyeloCelz™ (搜索) cell-free platform, which uses stem cell-programmed myeloid cell-derived exosomes to induce antigen-specific immune tolerance.
The patent complements the company's clinical-stage CELZ-201 (CREATE-1 trial) and CELZ-101 (FDA Orphan Drug Designation) diabetes programs.
Creative Medical Technology Holdings (搜索), Inc. (NASDAQ: CELZ) announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application titled "Suppression of Diabetes Using Exosomes From Stem Cell Programmed Myeloid Cells" (U.S. Application No. 17/931,868). The allowed patent covers the company's proprietary MyeloCelz™ (搜索) platform, a cell-free exosome technology designed to induce antigen-specific immune tolerance and suppress the autoimmune destruction of insulin-producing pancreatic beta cells (搜索) that underlies Type 1 diabetes (搜索) (T1D).
Once formally issued, the patent will extend Creative Medical's intellectual property protection around the MyeloCelz™ (搜索) platform. The allowed claims cover the use of stem cell-programmed myeloid cell-derived exosomes, either alone or in combination with other tolerance-promoting agents such as antibodies, cellular therapies, and small molecules. The approach aims to selectively shut down the immune cells responsible for attacking the pancreas while preserving the immune system's ability to fight infection and disease.
"Each new Notice of Allowance adds another layer of protection around the core biology that differentiates our platform," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings (搜索). "This exosome-based approach gives us a cell-free way to pursue the same antigen-specific tolerance mechanism we are already advancing clinically with CELZ-101 and CELZ-201. Building overlapping IP protection across both our cellular and cell-free diabetes programs is a deliberate strategy to maximize the long-term value of our platform for patients and shareholders alike."
Strengthening a Multi-Layered Patent Estate
This Notice of Allowance is the latest in a series of USPTO actions strengthening Creative Medical's intellectual property position across its immunology and endocrinology pipeline. It follows prior Notices of Allowance covering "Prevention and/or Treatment of Type 1 Diabetes (搜索) by Augmentation of Myeloid Suppressor Cell Activity" and "Treatment of Heart Failure and/or Post Infarct Pathological Remodeling by Ex Vivo Reprogrammed Immune Cells," both of which were subsequently issued as U.S. Patent Nos. 12,931,925 and 12,385,011, respectively, providing protection into 2042 and 2043.
The newly allowed exosome patent directly complements the company's broader diabetes portfolio, which spans multiple stages of disease and mechanisms of action. CELZ-201 (olastrocel/AlloStem®) is currently being evaluated in the FDA-cleared CREATE-1 trial for newly diagnosed T1D. CELZ-101 (etaroleucel/ImmCelz®) holds FDA Orphan Drug Designation for use alongside pancreatic islet transplantation in brittle T1D. Additionally, CELZ-001 represents the company's program for late-stage Type 2 diabetes.
Creative Medical's overall intellectual property estate now comprises approximately 60 issued patents and pending applications, with seven issued U.S. patents and 39 pending U.S. applications on file with the USPTO.
The Type 1 Diabetes Market Opportunity
Type 1 diabetes (搜索) remains a lifelong autoimmune condition with no approved cure. According to the U.S. Centers for Disease Control and Prevention, approximately 2.1 million Americans, including 1.8 million adults and 314,000 children and adolescents, are living with diagnosed T1D. Independent market research estimates the global Type 1 diabetes market at roughly $18 billion in 2026, with continued double-digit growth expected over the next several years as cell- and immune-based approaches advance through clinical development.
Current standard-of-care treatment remains centered on exogenous insulin replacement and non-specific immunosuppression, underscoring the unmet need for therapies aimed at inducing durable, antigen-specific immune tolerance — the mechanism Creative Medical's pipeline targets.
Strategic Path Forward
Following receipt of this Notice of Allowance, Creative Medical plans to complete formal issuance of the patent and continue building out its exosome-related intellectual property estate. The company will advance its clinical-stage CELZ-101 and CELZ-201 diabetes programs, including continued enrollment and data generation. Management also indicated that the expanded patent estate could support future licensing or partnership discussions, although no agreements have been announced.
While the intellectual property development strengthens the company's platform, the commercial value of these assets will ultimately depend on continued clinical progress, regulatory development, and successful execution of ongoing programs. MyeloCelz™ (搜索) remains investigational; no product has been approved, and the announcement includes no new clinical data or FDA authorization for the program.